Literature DB >> 15455960

Pancreatic tumors in patients with lung malignancies: a spectrum of clinicopathologic considerations.

Roderich E Schwarz1, Peiguo G Chu, Frederic W Grannis.   

Abstract

OBJECTIVES: Lung cancer and pancreatic cancer are the most lethal tobacco-associated malignancies. To elucidate possible clinical interrelationships, the authors reviewed the clinicopathologic characteristics of patients treated for both pulmonary and pancreatic neoplasms.
METHODS: Patients presenting with a potentially resectable pancreatic mass and a diagnosis of metachronous malignant neoplasm of the lung were studied by retrospective chart audit and review of histopathologic material.
RESULTS: Seven patients were identified over 6 years, representing five different clinical entities: metachronous presence of lung cancer and pancreatic cancer (n = 3), lung cancer metastatic to the pancreas (n = 1), lung cancer with a benign pancreatic neoplasm (n = 1), periampullary cancer metastatic to the lung (n = 1), and malignant melanoma metastatic to both lung and pancreas (n = 1). A tobacco history was present in all patients but one. Primary treatment modality was complete resection of isolated sites whenever feasible (lung resection, n = 6; pancreatic resection, n = 5). In four cases, a differential diagnosis of adenocarcinomas of both lung and pancreas was obtained after cytokeratin (CK) 7 and CK 20 immunohistochemistry. All patients with evidence of nodal or visceral metastasis from either primary site (n = 4) died within 5 to 9 months after the last operation. Three of four patients who had undergone resection of both pulmonary and pancreatic tumors were alive between 17 and 67 months after the last operation. All three survivors had presented with early disease stages and/or a protracted course (diagnostic interval, 16-66 months).
CONCLUSIONS: Our experience with neoplastic conditions that can involve lungs and pancreas metachronously may be useful to the clinician who is confronted with a similar situation. If therapeutic decision-making depends on differential diagnostic analysis, examination of CK 20 expression appears to be helpful. Although biologically favorable circumstances are rarely present, long-term survival seems possible after complete operative treatment in selected patients with early-stage disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15455960     DOI: 10.1097/01.SMJ.0000118129.88401.DB

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  6 in total

1.  Gastrointestinal bleeding due to pancreatic metastasis of non-small cell lung cancer: A report of two cases and a literature review.

Authors:  Yulong Zheng; Qiqi Gao; Weijia Fang; Nong Xu; Jianying Zhou
Journal:  Oncol Lett       Date:  2015-03-12       Impact factor: 2.967

Review 2.  Resection of isolated pancreatic metastases from pulmonary neoplasia: a systematic review.

Authors:  Isabel Jaén-Torrejimeno; Diego López-Guerra; Adela Rojas-Holguín; Noelia De-Armas-Conde; Gerardo Blanco-Fernández
Journal:  Updates Surg       Date:  2022-09-17

3.  Pulmonary adenocarcinoma occurring 5 years after resection of a primary pancreatic adenocarcinoma: a relevant differential diagnosis.

Authors:  R F Falkenstern-Ge; M Wohlleber; M Kimmich; K Huettl; G Friedel; G Ott; M Kohlhäufl
Journal:  Case Rep Oncol Med       Date:  2014-02-23

4.  Solitary Skull Metastasis as the First Presentation of a Metachronous Primary Lung Cancer in a Survivor from Pancreatic Cancer.

Authors:  Ali Altalhy; Yazid Maghrabi; Zuhoor Almansouri; Saleh S Baeesa
Journal:  Case Rep Oncol Med       Date:  2017-07-24

5.  Synchronous primary adenocarcinoma of the lung and pancreas: a case series and review of the literature.

Authors:  Akshjot Puri; Ly Ma; Gary V Walker; John Chang; Ron Z Shinar; Madappa N Kundranda
Journal:  Lung Cancer Manag       Date:  2017-07-14

Review 6.  Lung adenocarcinoma presenting as obstructive jaundice: a case report and review of literature.

Authors:  Stephanos Pericleous; Samrat Mukherjee; Robert R Hutchins
Journal:  World J Surg Oncol       Date:  2008-11-11       Impact factor: 2.754

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.